(Q34549913)

3 August 2017

1 reference

title

Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases (English)

1 reference

3 August 2017

1 reference

Dagmar Kubitza

1

1 reference

3 August 2017

Sylvia Haas

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Investigational Drugs

3 August 2017

published in

1 reference

3 August 2017

volume

15

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

843-855

1 reference

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Direct thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

What is all that thrombin for?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Coagulation factor Xa inhibition: biological background and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Importance of factor Xa in determining the procoagulant activity of whole-blood clots

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

The use of prothrombin(S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Secondary prophylaxis with warfarin for venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Thrombus formation in a living mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Current options in the prevention of thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.843

10.1517/13543784.15.8.843

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference